Ryboquin acquires Nanogenic Solutions for £4.45 million

The Scottish Biotech company Ryboquin has acquired Nanogenic Solutions, to form a new product and platform company, which, following acquisition will be named Nanogenics Limited. Ryboquin raised £4.45 million in its third funding round from new and existing share-holders to acquire Nanogenic Solutions.

The combined company is set to revolutionise gene therapy by pioneering the safe, efficacious and regular dosing of all forms of gene therapy.

[adbutler zone_id=’297765′]

Currently viruses and liposomes are used in this process, which have limited applications, severe side-effects and expensive technical problems. Nanogenics is developing LipTide, an artificial virus, which acts as a custom-built delivery system that can be modified to target different cell types and deliver different payloads, making the promise of gene therapy one step closer to reality.

LipTide is a protein based nanoparticle, which mimics natural viruses, but by-passes the many problems of viral delivery. The ability to regularly dose gene therapy payloads with LipTide™ could revolutionise the approach to gene therapy.

Dr Alan Walker, Chief Executive Officer, Nanogenics, says: “I am thrilled we have been able to combine these two businesses. It will offer real hope to those millions of patients living with diseases who have been unable to benefit from the advances in gene therapy because, until now, it has been so difficult to safely deliver the correct gene therapy to the right target. That can now change and we are already working with six major BioTech companies who want to access this exciting delivery mechanism.”

In addition to working with partners to deliver their gene therapy programmes, Nanogenics is developing its own product pipeline taking advantage of the revolutionary LipTide delivery platform. The lead programme, LipTide-ECP102, on which Nanogenics has US and EU patents, dramatically enhances chemotherapy and radiotherapy. A clinical trial is planned at the Christie Hospital Manchester in 2020. Currently LipTide-ECP102 is being scaled up to an industrial batch in collaboration with Strathclyde University.

Paul Murray, Executive Chairman, of the enlarged company, says: “We have worked hard and convinced investors of the huge potential of LipTide and we plan to grow the company quickly to a stage where we can take it public as soon as that is feasible. This is a great opportunity to generate real value by offsetting the high risk high return of product development with the amazing potential for multiple licence deals for the revolutionary LipTide platform. It is very rewarding to be involved in the cutting edge of medical science.”

[yikes-mailchimp form=”2″ title=”1″ description=”1″]

Sponsor

Our Other Titles

Latest

Work starts on public square at the heart of £1 billion Dundee Waterfront regeneration

WORK TO create a new public square and active travel hub at the heart of Dundee Waterfront’s £1 billion renaissance is now...

Cumbernauld’s New Retail Park Helps Boost Local Economy

CUMBERNAULD’S local economy is enjoying a significant economic boost from the completion of a £20 million retail development by London & Scottish...

Scottish Robotics Deal Programs £1 million Annually

SP TECHNOLOGY has today been announced as the first and only Scottish distribution partner of Collaborative robots, from Universal Robots, also known...

Global investment firm backs small UK producer in a bid to make the startup a billion-dollar no low alcohol brand

WITH THE rise and rise of the no and low alcohol category, global investment firm, Lightspeed Venture Partners, has handpicked new UK...

Assetz Capital provides £1million loan to fund new residential development

MARKETPLACE lender Assetz Capital has provided a loan in excess of £1m to Status Properties Ltd to help fund the development of new apartments on...